RecruitingNCT03175471

MRI Based Biomarkers in Pediatric Autoimmune Liver Disease

Cross-sectional Study for Assessment of MRI Based Biomarkers of Bile Duct Injury and Hepatic Fibrosis in Pediatric Onset Autoimmune Liver Disease


Sponsor

Children's Hospital Medical Center, Cincinnati

Enrollment

115 participants

Start Date

Jan 17, 2017

Study Type

OBSERVATIONAL

Conditions

Summary

Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factors for chronic liver disease among adolescents. In all these conditions, autoimmune lymphocyte responses are thought to orchestrate inflammatory injury against hepatocytes (primarily in AIH) or cholangiocytes (in PSC). In this proposal we aim to evaluate the Magnetic Resonance Imaging (MRI) modalities; MR cholangiopancreatography (MRCP) and MR elastography (MREL), as non-invasive biomarkers to assess two primary pathophysiological processes of AILD: bile duct damage and liver fibrosis. In this cross-sectional study MRI based findings of bile duct injury and liver fibrosis will be correlated with both liver histology and circulating biomarkers of these disease processes.


Eligibility

Min Age: 6 YearsMax Age: 23 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with autoimmune hepatitis, autoimmune liver disease, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 6 Years to 23 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Cincinnati Childrens Hospital Medical Center

Cincinnati, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03175471


Related Trials